A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Active:	Yes
Cancer Type:	Bladder Cancer Unknown Primary	NCT ID:	NCT05714202
Trial Phases:	Phase III	Protocol IDs:	CR109223 (primary) NCI-2023-05193 17000139BLC3002 2020-004506-64
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Janssen Research & Development, LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT05714202

Summary

The purpose of this study is to compare event-free survival (EFS) in participants with
Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer
(HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS),
between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical
BCG (Group B).

Objectives

Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of
bladder cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC
patients have HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an
intravesical drug delivery system regulated as an investigational drug. The drug
constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is
a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds
programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is
transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In
this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or
in combination with cetrelimab will be evaluated and compared against intravesical BCG.
The study consists of a Screening phase, Treatment phase, and Follow-up phase. The total
duration of the study will be up to 5 years and 2 months. Efficacy, Safety,
pharmacokinetics (PK), and biomarkers will be assessed at specific time points during the
study.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.